Source: s3://data.kl3m.ai/documents/govinfo/USCOURTS/USCOURTS-cand-4_17-cv-04405/USCOURTS-cand-4_17-cv-04405-29/pdf.json

Nature of Suit Code: 830
Nature of Suit: Patent
Cause of Action: 35:271 Patent Infringement

---

MCDERMOTT 

WILL 

& EMERY LLP 

ATTORNEYS AT LAW

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

- 1 -

ORDER GRANTING

MOTION TO REMOVE

CASE NO. 4:17-CV-04405-HSG

THOMAS P. STEINDLER (Pro Hac Vice)

tsteindler@mwe.com 

PAUL M. SCHOENHARD (Pro Hac Vice)

pschoenhard@mwe.com 

MICHAEL S. NADEL (Pro Hac Vice)

mnadel@mwe.com

IAN B. BROOKS (Pro Hac Vice)

ibrooks@mwe.com

JENNIFER ROUTH (Pro Hac Vice)

jrouth@mwe.com 

DAVID MLAVER (Pro Hac Vice)

dmlaver@mwe.com 

MCDERMOTT WILL & EMERY LLP 

500 N. Capitol St., N.W. 

Washington, DC 20001 

Tel: (202) 756-8000 

Fax: (202) 756-8087 

WILLIAM G. GAEDE III (SBN: 136184) 

wgaede@mwe.com

MCDERMOTT WILL & EMERY LLP 

275 Middlefield Road, Suite 100 

Menlo Park, CA 94025 

Tel: (650) 815-7400 

Fax: (650) 469-1470 

KATHERINE NICOLE CLOUSE (Pro Hac Vice) 

nclouse@mwe.com

MCDERMOTT WILL & EMERY LLP 

28 State Street 

Boston, MA 02109 

Tel: (617) 535-4000 

Fax: (617) 535-3800 

Attorneys for Defendant 

Novartis Pharmaceuticals Corporation

UNITED STATES DISTRICT COURT 

NORTHERN DISTRICT OF CALIFORNIA 

OAKLAND DIVISION 

PLEXXIKON INC., 

Plaintiff, 

v.

NOVARTIS PHARMACEUTICALS 

CORPORATION, 

Defendant.

CASE NO. 4:17-cv-04405-HSG 

ORDER GRANTING NOVARTIS’S 

MOTION TO REMOVE 

INCORRECTLY FILED DOCUMENT, 

ECF NO. 365 

Ctrm: 2 – 4th Floor 

Judge: Honorable Haywood S. Gilliam, Jr. 

Case 4:17-cv-04405-HSG Document 376 Filed 01/28/20 Page 1 of 2
MCDERMOTT 

WILL 

& EMERY LLP 

ATTORNEYS AT LAW

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

- 2 -

ORDER GRANTING

MOTION TO REMOVE

CASE NO. 4:17-CV-04405-HSG 

Having considered Defendant Novartis Pharmaceuticals Corporations (“Novartis”) motion 

to remove ECF No. 365 from the publicly-available docket on the basis that it contains 

information that has been designated as confidential by third-party GlaxoSmithKline (“GSK”), 

The Court, finding good cause therefor, GRANTS Novartis’ Motion to Remove Incorrectly Filed 

Document, and orders that ECF No. 365 be removed by the clerk from the publicly-available 

docket. 

IT IS ORDERED 

Dated: 1/28/2020

The Honorable Haywood S. Gilliam, Jr. 

UNITED STATES DISTRICT JUDGE 

Case 4:17-cv-04405-HSG Document 376 Filed 01/28/20 Page 2 of 2